4DX
Delivery · Highdata caveat$2.2B5mo
4DMedical
Medical Devices · Medical imaging
XV Technology for lung ventilation imaging and analytics
Data HealthTrials1 of 1 active · stale enrollment
Cash data from Dec 2025 4C(5mo old)Figures from ASX filings · not financial advice
[ VITALS ]
Cash on Hand
$4.3M
Dec 2025 4C
Runway
5moCRITICAL
Based on Dec 2025 4C
Market Cap
$2.2B
Burn Rate
$2.6M/qtr
Dec 2025 4C
Shares Outstanding
593M
Pipeline Assets
2
Latest Insightprice-sensitive announcements & broker notes
Price-sensitiveOther1 June 2026
4DMedical targets US$2.5B PE market entry for CTVQ
4DMedical launches CLEAR, a clinical evidence program to fast-track CT:VQ™ entry into the US pulmonary embolism (PE) market, expanding the addressable market from ~US$1B (nuclear VQ) to US$3B by competing against CTPA in the ~5 million annual PE scans market. The company has secured Mass General Brigham as lead site with US$2M committed funding for a prospective, head-to-head clinical study.
3M Price
4DX.ASX$3.650-13.5% 3M
Low $3.210High $6.800
Pipeline Assets (2)
Discovery
Preclinical
Ph 1
Ph 1/2
Ph 2
Ph 2/3
Ph 3
NDA
Capital Raises & Buybacks
12mo dilution 2.9%12mo $87M4 raises
Current shares outstanding: 593M
Placement
Options
Other
2026-06-01placement
Other ticker dataInsider activity, holders, grants, publications
expand ›
Insider activity, holders, grants, publications
Substantial Holders (5%+ threshold)
8 noticesINITIALState Street Corporation and subsidiaries
5.08%2026-05-28
INITIALCitigroup Global Markets Australia Pty Limited and related bodies corporate in the Citigroup group of companies worldwide
Catalysts (9)· 2 upcoming · 7 past
SpeculativeremoveMed31 May 2026
XV LVAS US reimbursement progress
UpcomingExpectedarrow_upwardHigh30 June 2026
expand_more7 past catalysts
Track RecordDelivery Consistency Index
expand ›
Delivery Consistency Index
Historical delivery and spending consistency. Data is limited for recently added companies.
Delivery Consistency Index
Delivery
High100/100
Timeline adherence · phase-adjusted tolerance · recency-weighted · min 3 catalysts
Capital discipline
High93/100
Burn rate stability · stage-adjusted thresholds · runway trend · R&D focus
Hit 7 of 7 guided dates· rolling 2yr· of 9 tracked
What drove these scores · rolling 2yr
arrow_drop_down
Cash position declining — Cash balance dropped >30% over last 3 quarters
arrow_drop_up
CT:VQ Phase 2 interim results — Delivered 135d early
arrow_drop_up
Reimbursement evidence development partnership with SimonMed — Delivered 728d early
arrow_drop_up
Stable burn rate — 23% quarterly variation — consistent spend
arrow_drop_up
R&D-focused spend — 72% of opex directed to R&D
·
CT:VQ™ MHRA — GSK contract, UK clearance for CTVQ, and ASX 200 inclusion — Delivered on time
·
CTVQ enters US Outpatient Market via SimonMed 170 sites — Delivered on time
·
4DMedical creates EU platform via contextflow acquisition — Delivered on time
·
Proposed issue of securities - 4DX — Delivered on time
·
Proposed issue of securities - 4DX — Delivered on time
·
Phase 3+ thresholds — Burn rate variability thresholds adjusted for late-stage development
Completed catalysts
✓CT:VQ™ MHRA — GSK contract, UK clearance for CTVQ, and ASX 200 inclusion— CT:VQ™ received UKCA certification for clinical use in the United Kingdom under the regulatory oversight of the Medicines and Healthcare products Regulatory Agency (MHRA), following CE Mark certification in March 2026. This clearance allows immediate commercial deployment of CT:VQ™ across public and private healthcare providers in the UK.
On time
✓CTVQ enters US Outpatient Market via SimonMed 170 sites— 4DMedical has secured a commercial agreement with SimonMed Imaging to deploy CT:VQ™ and LDAf™ across SimonMed's 170+ outpatient imaging centers in the US. The three-year deal involves immediate commercial deployment on per-scan pricing terms and includes partnership to develop reimbursement evidence, representing a material long-term opportunity for 4DMedical.
On time
✓4DMedical creates EU platform via contextflow acquisition· partnership — counterparty-driven— 4DMedical agreed to acquire Austrian-based medical imaging AI company contextflow GmbH for approximately A$18.56 million cash plus 56,235 shares upfront, with contingent earnout options of up to 2,589,247 zero exercise price options subject to performance milestones, establishing an immediate European commercial platform for lung health imaging.
On time
✓Proposed issue of securities - 4DX
On time
✓Proposed issue of securities - 4DX
On time
✓CT:VQ Phase 2 interim results· readout — subject to clinical uncertainty— CT:VQ technology has been validated in a peer-reviewed publication in the American Journal of Respiratory and Critical Care Medicine, demonstrating 76% response rate versus 46% with current methods for lung volume reduction surgery patient selection.
135d early
✓Reimbursement evidence development partnership with SimonMed— 4DMedical launched the CLEAR clinical evidence program with Mass General Brigham as lead site and US$2M committed funding for a prospective, head-to-head study to generate reimbursement evidence for CT:VQ entry into the US PE market.
728d early
Outcome quality (positive/negative readouts) reflects the science, not execution — shown above but excluded from the score.
These metrics reflect historical operational data only. They are not predictive of future performance, do not constitute investment advice, and should not be used as the basis for any investment decision.
Clinical Trials(2)
1 activeClinicalTrials.gov ↗
RecruitingOBSERVATIONALEnrollment stale · 1101d
Computed Tomography of the Chest
Ventilatory and Perfusion Abnormalities in Individuals With Post-Acute Sequelae of SARS-CoV-2 Infection
Post-Acute COVID-19 · Post COVID-19 Condition · Post Viral Fatigue +1 more
18 Years – 99 Years
Primary endpoint Measures of regional lung ventilation
ENROL40
no manual snapshots — enter via record_enrollment.py
Announcements(20)
article
OtherPSauto_awesome
4DMedical targets US$2.5B PE market entry for CTVQ1 June 2026
expand_more235KB
handshake
PartnershipPSauto_awesome
4DMedical creates EU platform via contextflow acquisition31 May 2026
expand_more297KB